Cargando…

Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation

BACKGROUND: Neuroinflammation occurs as a result of microglial activation in response to invading micro-organisms or other inflammatory stimuli within the central nervous system. According to our earlier findings, Krüppel-like factor 4 (Klf4), a zinc finger transcription factor, is involved in micro...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaushik, Deepak Kumar, Mukhopadhyay, Rupanjan, Kumawat, Kanhaiya Lal, Gupta, Malvika, Basu, Anirban
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325890/
https://www.ncbi.nlm.nih.gov/pubmed/22429472
http://dx.doi.org/10.1186/1742-2094-9-57
_version_ 1782229463679893504
author Kaushik, Deepak Kumar
Mukhopadhyay, Rupanjan
Kumawat, Kanhaiya Lal
Gupta, Malvika
Basu, Anirban
author_facet Kaushik, Deepak Kumar
Mukhopadhyay, Rupanjan
Kumawat, Kanhaiya Lal
Gupta, Malvika
Basu, Anirban
author_sort Kaushik, Deepak Kumar
collection PubMed
description BACKGROUND: Neuroinflammation occurs as a result of microglial activation in response to invading micro-organisms or other inflammatory stimuli within the central nervous system. According to our earlier findings, Krüppel-like factor 4 (Klf4), a zinc finger transcription factor, is involved in microglial activation and subsequent release of proinflammatory cytokines, tumor necrosis factor alpha, macrophage chemoattractant protein-1 and interleukin-6 as well as proinflammatory enzymes, inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-treated microglial cells. Our current study focuses on finding the molecular mechanism of the anti-inflammatory activities of honokiol in lipopolysaccharide-treated microglia with emphasis on the regulation of Klf4. METHODS: For in vitro studies, mouse microglial BV-2 cell lines as well as primary microglia were treated with 500 ng/mL lipopolysaccharide as well as 1 μM and 10 μM of honokiol. We cloned full-length Klf4 cDNA in pcDNA3.1 expression vector and transfected BV-2 cells with this construct using lipofectamine for overexpression studies. For in vivo studies, brain tissues were isolated from BALB/c mice treated with 5 mg/kg body weight of lipopolysaccharide either with or without 2.5 or 5 mg/kg body weight of honokiol. Expression of Klf4, cyclooxygenase-2, inducible nitric oxide synthase and phospho-nuclear factor-kappa B was measured using immunoblotting. We also measured the levels of cytokines, reactive oxygen species and nitric oxide in different conditions. RESULTS: Our findings suggest that honokiol can substantially downregulate the production of proinflammatory cytokines and inflammatory enzymes in lipopolysaccharide-stimulated microglia. In addition, honokiol downregulates lipopolysaccharide-induced upregulation of both Klf4 and phospho-nuclear factor-kappa B in these cells. We also found that overexpression of Klf4 in BV-2 cells suppresses the anti-inflammatory action of honokiol. CONCLUSIONS: Honokiol potentially reduces inflammation in activated microglia in a Klf4-dependent manner.
format Online
Article
Text
id pubmed-3325890
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33258902012-04-14 Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation Kaushik, Deepak Kumar Mukhopadhyay, Rupanjan Kumawat, Kanhaiya Lal Gupta, Malvika Basu, Anirban J Neuroinflammation Research BACKGROUND: Neuroinflammation occurs as a result of microglial activation in response to invading micro-organisms or other inflammatory stimuli within the central nervous system. According to our earlier findings, Krüppel-like factor 4 (Klf4), a zinc finger transcription factor, is involved in microglial activation and subsequent release of proinflammatory cytokines, tumor necrosis factor alpha, macrophage chemoattractant protein-1 and interleukin-6 as well as proinflammatory enzymes, inducible nitric oxide synthase and cyclooxygenase-2 in lipopolysaccharide-treated microglial cells. Our current study focuses on finding the molecular mechanism of the anti-inflammatory activities of honokiol in lipopolysaccharide-treated microglia with emphasis on the regulation of Klf4. METHODS: For in vitro studies, mouse microglial BV-2 cell lines as well as primary microglia were treated with 500 ng/mL lipopolysaccharide as well as 1 μM and 10 μM of honokiol. We cloned full-length Klf4 cDNA in pcDNA3.1 expression vector and transfected BV-2 cells with this construct using lipofectamine for overexpression studies. For in vivo studies, brain tissues were isolated from BALB/c mice treated with 5 mg/kg body weight of lipopolysaccharide either with or without 2.5 or 5 mg/kg body weight of honokiol. Expression of Klf4, cyclooxygenase-2, inducible nitric oxide synthase and phospho-nuclear factor-kappa B was measured using immunoblotting. We also measured the levels of cytokines, reactive oxygen species and nitric oxide in different conditions. RESULTS: Our findings suggest that honokiol can substantially downregulate the production of proinflammatory cytokines and inflammatory enzymes in lipopolysaccharide-stimulated microglia. In addition, honokiol downregulates lipopolysaccharide-induced upregulation of both Klf4 and phospho-nuclear factor-kappa B in these cells. We also found that overexpression of Klf4 in BV-2 cells suppresses the anti-inflammatory action of honokiol. CONCLUSIONS: Honokiol potentially reduces inflammation in activated microglia in a Klf4-dependent manner. BioMed Central 2012-03-19 /pmc/articles/PMC3325890/ /pubmed/22429472 http://dx.doi.org/10.1186/1742-2094-9-57 Text en Copyright ©2012 Kaushik et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Kaushik, Deepak Kumar
Mukhopadhyay, Rupanjan
Kumawat, Kanhaiya Lal
Gupta, Malvika
Basu, Anirban
Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation
title Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation
title_full Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation
title_fullStr Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation
title_full_unstemmed Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation
title_short Therapeutic targeting of Krüppel-like factor 4 abrogates microglial activation
title_sort therapeutic targeting of krüppel-like factor 4 abrogates microglial activation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3325890/
https://www.ncbi.nlm.nih.gov/pubmed/22429472
http://dx.doi.org/10.1186/1742-2094-9-57
work_keys_str_mv AT kaushikdeepakkumar therapeutictargetingofkruppellikefactor4abrogatesmicroglialactivation
AT mukhopadhyayrupanjan therapeutictargetingofkruppellikefactor4abrogatesmicroglialactivation
AT kumawatkanhaiyalal therapeutictargetingofkruppellikefactor4abrogatesmicroglialactivation
AT guptamalvika therapeutictargetingofkruppellikefactor4abrogatesmicroglialactivation
AT basuanirban therapeutictargetingofkruppellikefactor4abrogatesmicroglialactivation